stockrow
Friday 6 November 2026
Export UPC’s income statement to Excel — free account
Universe Pharmaceuticals INC
UPC Healthcare Drug Manufacturers Specialty & Generic
Universe Pharmaceuticals INC’s revenue for fiscal 2025 (year ended September 2025) was $17.9 million, down 22.4% from fiscal 2024.
1.35
0.05
−3.57%
Follow UPC
Alert me
Universe Pharmaceuticals INC (UPC) P/E ratio
Universe Pharmaceuticals INC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 9,177× (November 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 2,865× | 0.00% |
| FY2021 | 2,865× | 61,412.84% |
| FY2020 | 4.7× | 0.00% |
| FY2019 | 4.7× | 0.00% |
| FY2018 | 4.7× | 0.00% |
| FY2018 | 4.7× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2023 | 0.0× | — |
| Sep 2022 | 2,865× | 0.00% |
| Mar 2022 | 2,865× | 0.00% |
| Sep 2021 | 2,865× | 72,769.43% |
| 1 more quarters | Free account |
Against its own ten years
Low 0.0×
High 9,177×
Ten-year median
0.0×
Current reading's percentile
86
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BFRI Biofrontera Inc. compare | n/m |
| UPC Universe Pharmaceuticals INC | n/m |
| APUS Apimeds Pharmaceuticals US, Inc. compare | n/m |
| SNOA Sonoma Pharmaceuticals, Inc. compare | n/m |
| YCBD cbdMD, Inc. compare | n/m |
| INM InMed Pharmaceuticals Inc. compare | n/m |
| RDHL Redhill Biopharma Ltd. compare | n/m |
| OPTH Optimi Health Corp. compare | — |
| GELS Gelteq Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)